Identification and characterization of efflux transporters that modulate the subtoxic disposition of diclofenac and its metabolites

Abstract

In the present work, in vivo transporter knockout (KO) mouse models were used to characterize the disposition of diclofenac (DCF) and its primary metabolites following a single subtoxic dose in mice lacking breast cancer resistance protein (Bcrp) or multidrug resistance-associated protein (Mrp)3. The results indicate that Bcrp acts as a canalicular efflux mediator for DCF, as wild-type (WT) mice had biliary excretion values that were 2.2-to 2.6-fold greater than Bcrp KO mice, although DCF plasma levels were not affected. The loss of Bcrp resulted in a 1.8-to 3.2-fold increase of diclofenac acyl glucuronide (DCF-AG) plasma concentrations in KO animals compared with WT mice, while the biliary excretion of DCF-AG increased 1.4-fold in WT versus KO mice. Furthermore, Mrp3 was found to mediate the basolateral transport of DCF-AG, but not DCF or 4'-hydroxy diclofenac. WT mice had DCF-AG plasma concentrations 7.0-to 8.6-fold higher than Mrp3 KO animals; however, there were no changes in biliary excretion of DCF-AG. Vesicular transport experiments with human MRP3 demonstrated that MRP3 is able to transport DCF-AG via low-and high-affinity binding sites. The lowaffinity MRP3 transport had a Vmax and Km of 170 pmol/min/mg and 98.2 mM, respectively, while the high-affinity Vmax and Km parameters were estimated to be 71.9 pmol/min/mg and 1.78 mM, respectively. In summary, we offer evidence that the disposition of DCF-AG can be affected by both Bcrp andMrp3, and these findings may be applicable to humans.